{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:49:07Z","timestamp":1790225347953,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Travel Medicine and Infectious Disease"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.tmaid.2016.06.005","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T20:02:49Z","timestamp":1466712169000},"page":"378-383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Dengue vaccines: Are they safe for travelers?"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7818-348X","authenticated-orcid":false,"given":"Scott B.","family":"Halstead","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maira","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7446","key":"10.1016\/j.tmaid.2016.06.005_bib1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.tmaid.2016.06.005_bib2","doi-asserted-by":"crossref","first-page":"e1760","DOI":"10.1371\/journal.pntd.0001760","article-title":"Refining the global spatial limits of dengue virus transmission by evidence-based consensus","volume":"6","author":"Brady","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"12 Suppl.","key":"10.1016\/j.tmaid.2016.06.005_bib3","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/nrmicro2460","article-title":"Dengue: a continuing global threat","volume":"8","author":"Guzman","year":"2010","journal-title":"Nat Rev Microbiol"},{"issue":"Suppl. 1","key":"10.1016\/j.tmaid.2016.06.005_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1179\/2046904712Z.00000000050","article-title":"Dengue infections in travellers","volume":"32","author":"Wilder-Smith","year":"2012","journal-title":"Paediatr Int Child Health"},{"issue":"330","key":"10.1016\/j.tmaid.2016.06.005_bib9","doi-asserted-by":"crossref","first-page":"330ra36","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine tv003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.tmaid.2016.06.005_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/14760584.2016.1128328","article-title":"A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone","volume":"15","author":"Osorio","year":"2016","journal-title":"Expert Rev Vaccines"},{"issue":"50","key":"10.1016\/j.tmaid.2016.06.005_bib11","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2015.09.108","article-title":"Development of the sanofi pasteur tetravalent dengue vaccine: one more step forward","volume":"33","author":"Guy","year":"2015","journal-title":"Vaccine"},{"issue":"9853","key":"10.1016\/j.tmaid.2016.06.005_bib12","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, cyd tetravalent dengue vaccine in thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"issue":"9951","key":"10.1016\/j.tmaid.2016.06.005_bib13","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.tmaid.2016.06.005_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in latin america","volume":"372","author":"Villar","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.tmaid.2016.06.005_bib15","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmaid.2016.06.005_bib16","series-title":"Background paper on dengue vaccines","author":"SAGE Working Group on Dengue Vaccines and WHO Secretariat","year":"2016"},{"issue":"14","key":"10.1016\/j.tmaid.2016.06.005_bib17","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.vaccine.2016.02.004","article-title":"Protective and immunological behavior of chimeric yellow fever dengue vaccine","volume":"34","author":"Halstead","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.tmaid.2016.06.005_bib18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0065-3527(03)60011-4","article-title":"Neutralization and antibody dependent enhancement of dengue viruses","volume":"60","author":"Halstead","year":"2003","journal-title":"Adv Virus Res"},{"issue":"6","key":"10.1016\/j.tmaid.2016.06.005_bib19","first-page":"997","article-title":"Dengue and chikungunya virus infection in man in thailand, 1962\u20131964: iv. Epidemiologic studies in the bangkok metropolitan area","volume":"18","author":"Halstead","year":"1969","journal-title":"AmJTropMedHyg"},{"issue":"304","key":"10.1016\/j.tmaid.2016.06.005_bib20","doi-asserted-by":"crossref","first-page":"304ra141","DOI":"10.1126\/scitranslmed.aaa3787","article-title":"Dengue virus non-structural protein 1 triggers endothelial permeability and vascular leak that can be inhibited by anti-ns1 antibodies","volume":"7","author":"Beatty","year":"2015","journal-title":"Sci Transl Med"},{"issue":"304","key":"10.1016\/j.tmaid.2016.06.005_bib21","doi-asserted-by":"crossref","first-page":"304ra142","DOI":"10.1126\/scitranslmed.aaa3863","article-title":"Dengue virus ns1 is a viral toxin that activates cells via tlr4 and disrupts endothelial cell monolayer integrity","volume":"7","author":"Modhiran","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tmaid.2016.06.005_bib22","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.7024.1","article-title":"Pathogenesis of dengue: dawn of a new era","volume":"4","author":"Halstead","year":"2015","journal-title":"F1000Res"},{"key":"10.1016\/j.tmaid.2016.06.005_bib23","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1073\/pnas.88.12.5139","article-title":"Infectious rna transcribed from stably cloned full-length cdna of dengue type 4 virus","volume":"88","author":"Lai","year":"1991","journal-title":"ProcNatlAcadSciUSA"},{"key":"10.1016\/j.tmaid.2016.06.005_bib24","doi-asserted-by":"crossref","first-page":"10342","DOI":"10.1073\/pnas.88.22.10342","article-title":"Construction of intertypic chimeric dengue viruses by substitution of structural protein genes","volume":"88","author":"Bray","year":"1991","journal-title":"ProcNatlAcadSciUSA"},{"key":"10.1016\/j.tmaid.2016.06.005_bib25","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1128\/jvi.70.6.3930-3937.1996","article-title":"Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the rna genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys","volume":"70","author":"Men","year":"1996","journal-title":"JVirol"},{"issue":"5","key":"10.1016\/j.tmaid.2016.06.005_bib26","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1086\/427780","article-title":"Rden4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers","volume":"191","author":"Durbin","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tmaid.2016.06.005_bib27","first-page":"145","article-title":"Targeted mutagenesis as a rational approach to dengue virus vaccine development","volume":"338","author":"Blaney","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.tmaid.2016.06.005_bib28","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1128\/jvi.69.8.5186-5190.1995","article-title":"Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice","volume":"69","author":"Chen","year":"1995","journal-title":"JVirol"},{"issue":"1","key":"10.1016\/j.tmaid.2016.06.005_bib29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/vim.2006.19.10","article-title":"Development of a live attenuated dengue virus vaccine using reverse genetics","volume":"19","author":"Blaney","year":"2006","journal-title":"Viral Immunol"},{"issue":"6","key":"10.1016\/j.tmaid.2016.06.005_bib30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4161\/hv.2.6.3494","article-title":"Rden2\/4delta30(me), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults","volume":"2","author":"Durbin","year":"2006","journal-title":"Hum Vaccin"},{"issue":"6","key":"10.1016\/j.tmaid.2016.06.005_bib31","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.vaccine.2007.11.082","article-title":"Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3\u2032 untranslated region (3\u2032-utr) or by exchange of the denv-3 3\u2032-utr with that of denv-4","volume":"26","author":"Blaney","year":"2008","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.tmaid.2016.06.005_bib32","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1016\/j.vaccine.2013.05.075","article-title":"Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles","volume":"31","author":"Lindow","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.tmaid.2016.06.005_bib33","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults","volume":"212","author":"Kirkpatrick","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tmaid.2016.06.005_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiw067","article-title":"A 12-month interval dosing study in adults indicates that a single dose of the niaid tetravalent dengue vaccine induces a robust neutralizing antibody response","author":"Durbin","year":"2016","journal-title":"J Infect Dis"},{"issue":"14","key":"10.1016\/j.tmaid.2016.06.005_bib35","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1128\/JVI.00273-15","article-title":"Complexity of neutralization antibodies against multiple dengue viral serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies","volume":"89","author":"Tsai","year":"2015","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.tmaid.2016.06.005_bib36","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1128\/JVI.02129-14","article-title":"The human cd8+ t cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes","volume":"89","author":"Weiskopf","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.tmaid.2016.06.005_bib37","first-page":"189","article-title":"Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-pdk 53): clinical, immunological and biological responses in adult volunteers","volume":"65","author":"Bhamarapravati","year":"1987","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.tmaid.2016.06.005_bib38","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0264-410X(95)00167-Y","article-title":"Testing of a dengue 2 live-attenuated vaccine (strain 16681 pdk 53) in ten american volunteers","volume":"14","author":"Vaughn","year":"1996","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.tmaid.2016.06.005_bib39","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1006\/viro.1997.8500","article-title":"Construction of infectious cdna clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain pdk-53","volume":"230","author":"Kinney","year":"1997","journal-title":"Virology"},{"issue":"2\u20133","key":"10.1016\/j.tmaid.2016.06.005_bib40","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000050045","article-title":"Development of new vaccines against dengue fever and japanese encephalitis","volume":"44","author":"Kinney","year":"2001","journal-title":"Intervirology"},{"issue":"7","key":"10.1016\/j.tmaid.2016.06.005_bib41","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1128\/JVI.74.7.3011-3019.2000","article-title":"Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (pdk-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3","volume":"74","author":"Butrapet","year":"2000","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.tmaid.2016.06.005_bib42","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1128\/JVI.74.7.3020-3028.2000","article-title":"Chimeric dengue type 2 (vaccine strain pdk-53)\/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine","volume":"74","author":"Huang","year":"2000","journal-title":"J Virol"},{"issue":"21","key":"10.1016\/j.tmaid.2016.06.005_bib43","doi-asserted-by":"crossref","first-page":"11436","DOI":"10.1128\/JVI.77.21.11436-11447.2003","article-title":"Dengue 2 pdk-53 virus as a chimeric carrier for tetravalent dengue vaccine development","volume":"77","author":"Huang","year":"2003","journal-title":"J Virol"},{"issue":"50","key":"10.1016\/j.tmaid.2016.06.005_bib44","doi-asserted-by":"crossref","first-page":"7112","DOI":"10.1016\/j.vaccine.2015.11.022","article-title":"Development of a recombinant, chimeric tetravalent dengue vaccine candidate","volume":"33","author":"Osorio","year":"2015","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.tmaid.2016.06.005_bib45","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1016\/j.vaccine.2014.08.087","article-title":"Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against denv-4 challenge in AG129 mice","volume":"32","author":"Fuchs","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.tmaid.2016.06.005_bib46","series-title":"Department of immunization VaB","first-page":"441","article-title":"Guidelines for the clinical evaluation of dengue vaccines in endemic areas","author":"WHO","year":"2008"},{"issue":"33","key":"10.1016\/j.tmaid.2016.06.005_bib47","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1016\/j.vaccine.2008.05.058","article-title":"\u201cGuidelines for the clinical evaluation of dengue vaccines in endemic areas\u201d: summary of a world health organization technical consultation","volume":"26","author":"Edelman","year":"2008","journal-title":"Vaccine"},{"issue":"46 Suppl.","key":"10.1016\/j.tmaid.2016.06.005_bib48","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S1386-6532(09)70287-2","article-title":"Guidelines for clinical trials of dengue vaccine in endemic areas","volume":"2","author":"Hombach","year":"2009","journal-title":"J Clin Virol"},{"issue":"1","key":"10.1016\/j.tmaid.2016.06.005_bib49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrmicro.2015.2","article-title":"Dengue vaccine: hypotheses to understand cyd-tdv-induced protection","volume":"14","author":"Guy","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.tmaid.2016.06.005_bib50","unstructured":"anonymous. Http:\/\/www.Who.Int\/immunization\/sage\/meetings\/2016\/april\/sage_april_2016_meeting_web_summary.Pdf?Ua=1. ed.\u02c6,eds. WHO, Geneva, 2016."},{"issue":"14","key":"10.1016\/j.tmaid.2016.06.005_bib51","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/S0264-410X(97)00195-3","article-title":"Vaccine development against dengue and japanese encephalitis: report of a world health organization meeting","volume":"15","author":"Chambers","year":"1997","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.tmaid.2016.06.005_bib52","doi-asserted-by":"crossref","first-page":"E2046","DOI":"10.1073\/pnas.1305227110","article-title":"Comprehensive analysis of dengue virus-specific responses supports an hla-linked protective role for cd8+ t cells","volume":"110","author":"Weiskopf","year":"2013","journal-title":"Proc Natl Acad Sci U. S. A"},{"issue":"19","key":"10.1016\/j.tmaid.2016.06.005_bib53","doi-asserted-by":"crossref","first-page":"11383","DOI":"10.1128\/JVI.01108-14","article-title":"Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection","volume":"88","author":"Weiskopf","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.tmaid.2016.06.005_bib54","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/infdis\/jiv289","article-title":"Human cd8+ t-cell responses against the 4 dengue virus serotypes are associated with distinct patterns of protein targets","volume":"212","author":"Weiskopf","year":"2015","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.tmaid.2016.06.005_bib55","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1128\/JVI.74.12.5477-5485.2000","article-title":"Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates","volume":"74","author":"Guirakhoo","year":"2000","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.tmaid.2016.06.005_bib56","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (chimerivax-den2) vaccine: phase i clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Hum Vaccin"},{"issue":"42","key":"10.1016\/j.tmaid.2016.06.005_bib57","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1016\/j.vaccine.2011.07.023","article-title":"Development and clinical evaluation of multiple investigational monovalent denv vaccines to identify components for inclusion in a live attenuated tetravalent denv vaccine","volume":"29","author":"Durbin","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.tmaid.2016.06.005_bib58","series-title":"Dengue health map","author":"Centers for Disease Control and Prevention","year":"2016"},{"key":"10.1016\/j.tmaid.2016.06.005_bib59","series-title":"Travel and dengue outbreaks","author":"Centers for Disease Control and Prevention","year":"2016"}],"container-title":["Travel Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893916300710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893916300710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:01:26Z","timestamp":1761487286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1477893916300710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1477893916300710"],"URL":"https:\/\/doi.org\/10.1016\/j.tmaid.2016.06.005","relation":{},"ISSN":["1477-8939"],"issn-type":[{"value":"1477-8939","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dengue vaccines: Are they safe for travelers?","name":"articletitle","label":"Article Title"},{"value":"Travel Medicine and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmaid.2016.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}